◆ mixed
Impact
PhasePhase 2 (registrational-intent in PCNSL)
Time to marketUncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
emavusertib Updated Nov 15
What to watch
The next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).
Bull case
- 86% objective response rate in BTK-naive PCNSL patients from the TakeAim Lymphoma study is a strong efficacy signal in a difficult-to-treat cancer with few approved options
- The TakeAim Lymphoma study is designed as registrational, meaning positive data could directly support an NDA submission for FDA approval
- Analyst consensus leans bullish: 2 Strong Buy and 6 Buy ratings vs 1 Hold, with a mean price target of $30.33 (though the stock trades near $0.44)
Bear case
- Curis received a Nasdaq delisting notice on November 2, 2026 for failing the $1 minimum bid price, putting the listing at risk without a reverse split
- The stock closed at $0.445 on November 13, 2026, down ~99% from its 52-week high of $28.40, indicating severe investor skepticism
- The company has repeatedly tapped equity markets for capital ($8.5M private placement in Oct 2026, $5.6M public offering in Aug 2026), causing heavy dilution to existing shareholders